Pharma Journalist

Wet AMD & DME Drug Development Summit
2022-04-05 - 2022-04-07 | Embassy Suites by Hilton Boston Logan Airport, 207 Porter St., Boston, MA, 02128, United States
Accelerating the Development of Novel Anti-VEGF, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden, Widen Therapeutic Index & Treatment Options for Non-responders
The second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-, inflammatory-directed and anti-fibrotic drug development programmes for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).
The 2022 Summit will include interactive presentations and panel discussions, covering challenging questions for the whole research community such as:

What are the future directions for anti-VEGF therapy to increase patient response rates, prolong treatment durability and reduce clinical burden?
Where is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?
What interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?
How are drug developers using various drug delivery methods – topical, intravitreal, suprachoroidal, port delivery – to expand the therapeutic window?
How has optical coherence tomography (OCT) imaging, including at-home diagnostic testing, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?

As the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted, identify the latest clinical data from anti-VEGF suppression (antibody fragments, delivery systems, bispecific antibodies, gene therapy), combinational approaches, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies.
Meet the leading ophthalmology drug developers from big pharma, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators, clinicians and payers.
Join us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation.
To know more visit: https://ter.li/m98rr7

Purify’22
2022-04-07 | ITC Kohenur,Hyderabad
PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups!
The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification.
The attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches, niche topics, deeper understanding of preparative and process chromatography and allied fields, and upcoming application areas that will provide quality substance to the discerning scientists. So, if you wish to get that additional gram, which is purer, in as less a time, with minimal resources…there will surely be something for you at PURIFY conclaves!
The annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP, a Mumbai based company.
The PURIFY conclave is attended by analytical and research chemists, scientists with scale-up and process development knowledge, managers, group heads, natural product purification experts, experts from quality and manufacturing, academicians, policy makers, supply chain heads etc. of this pharmaceutical – APIs, peptides, proteins, oligonucleotides, chiral molecules, bio-pharmaceutical, fine chemicals, environmental studies, food and beverage, polymers, biotechnology, cosmetics and fragrance to understand the advancements in chromatography platforms.
The maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers, steered by our esteemed advisory board.
PURIFY’19 was attended by 113 delegates across 19 cities, spread across 51 corporates with 14 speakers and 6 display zones!
So, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
Download Brochure

LNP Formulation & Process Development Summit
2022-04-12 - 2022-04-14 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Embrace Technology Innovations to Optimize LNP Formulation, Alternative LNP Raw Materials, Process Control to Achieve Seamless Scale-Up, Compliance & Cost Effectiveness
The inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. Across 3 days, you will address challenges and seek solutions to help you optimize your formulation to enhance stability, efficacy, and better characterization for drug product quality. This is your chance to explore the use of alternative polymer lipids to maximize scalability and moving towards cGMP manufacturing for pipeline progression.
The global nanopharmaceutical drugs market, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines, is poised to reach US$82.7 billion by 2027. The demand of novel LNP to support the delivery of oligonucleotide and nucleic acid-based therapies is growing at an exponential rate. With the overwhelming possibilities of lipid nanoparticles, there are key questions on formulation, process development and scalability that still need to be answered. There has been no better time to join forces and help accelerate the development of truly remedial LNP therapeutics.
To know more visit: https://ter.li/8hrml3

2nd Gene Therapy Medical Affairs Summit
2022-04-19 - 2022-04-21 | Westin Boston Seaport Hotel, 425 Summer St, Boston, MA, 02210, United States
Transforming Traditional Medical Affairs
Optimize Medical Affairs Proactive Engagements and Education Initiatives to Successfully Launch the Next Generation of Gene Therapy Products
The 2nd Annual Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients. This is your opportunity to take inspiration from Medical Affairs leaders of the gene therapy world and learn how traditional Medical Affairs approaches are being transformed to meet the unique challenges associated with gene therapy drug development.
Gain actionable insights from first-to-market pioneers, who will share how to engage effectively with internal clinical, commercial and regulatory teams as well as external HCPs, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex, high priced Gene Therapy products.
The summit will provide a dedicated platform that discusses the role and value of Medical Affairs across each of the phases of the gene therapy development cycle. We will delve into the unique challenges encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space, to handling long-term follow up and post-launch regulatory scrutiny, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before.
To know more visit: https://ter.li/xciowp

CPhI & P-MEC China Virtual Expo Connect
2022-04-21 - 2022-06-30 | Online
This year CPhI & P-MEC China returns as a SMART event, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period.

“Virtual Expo Connect”, to be held from 21st April – 30th June 2022, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals.
Powered by PharmaSources.com, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect, learn, trade and grow.
To know more visit: https://www.pharmasources.com/vec2022

SMi’s 9th Annual Conference Pre-Filled Syringes East Coast
2022-04-25 - 2022-04-26 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
SMi’s 9th Annual Conference
Pre-Filled Syringes East Coast
Main Conference: April 25 – 26, 2022 | Workshops: April 27, 2022
Sheraton Boston Hotel, Boston, MA, USA
www.pfsamericas.com/pharmajournalistwl
Sponsors are: SCHOTT, ZEON
Exhibitors: Owen Mumford Pharmaceutical Services, PHC Corporation, POLYPLASTICS- TOPAS, Weiss-Aug Group
Device innovations, connected delivery and regulatory guidance for advanced parenteral systems
The global pre-filled syringes market was valued at $1139.6 million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. With that in mind, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry.
The past year has seen significant developments in the injectables landscape with the rapid introduction and development of vaccines in response to the pandemic, updates in regulations including the EU MDR and FDA guidance on bridging studies, and increasing industry acceptance of connectivity to aid the user experience. As part of SMi’s leading injectable series, the 2022 conference will provide an exclusive insight into the latest developing technologies for device design, advances in parenteral device platforms and development, insights into growing integration of digital health and deep dives into recent case studies on novel delivery systems.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
Visit the website at: www.pfsamericas.com/pharmajournalistwl
Chair for 2022:
Gretchen Vandal, Sr. Director, Head of Global Regulatory Affairs – Devices and Combination Products, Takeda
Guest FDA Speaker:

John Barr Weiner, Associate Director for Policy and Product Classification Office, Office of Combination Products FDA

Featured 2022 Speakers Include:

Joyce Zhao, Associate Director, Combination Product, Takeda
Suzette Roan, Associate VP and Head of Global Device Regulatory Affairs, Sanofi US
Christine lynn lanning, Distinguished Scientist, Device Area Leader, Merck
Heather l. Guerin, Associate Director, Regulatory Affairs – CMC, JanssenTieming Ruan, Senior Director of Device Development, Alexion Pharmaceuticals
John Schalago, Executive Director, Senior Global Program Director Regulatory Affairs, Novartis
Gretchen Piwinski, Manager, Combination Product Laboratories, Regeneron
Michael Song, Associate Director, Takeda
Deep S Bhattacharya, Senior Scientist, Drug Product Development and Design, Pfizer

BENEFITS OF ATTENDING:

Explore the latest developments in innovative technologies for device design accelerating the path to self-administration
Assess the evolving regulatory landscape for pre-filled syringes and discuss approaches to work with regulators as guidance is updated
Engage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drug delivery systems
Understand the landscape of delivery for novel drug products and key considerations to overcome challenges in CCI

View the full agenda and speaker line-up online: www.pfsamericas.com/pharmajournalistwl
Who should Attend:

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

EARLY-BIRD RATES:

BOOK BY 17th DECEMBER AND SAVE $400
BOOK BY 31st JANUARY AND SAVE $200
BOOK BY 28TH FEBRUARY AND SAVE $100

Registrations can be made on the event website at: www.pfsamericas.com/pharmajournalistwl

2nd Chronic HBV Drug Development Summit
2022-04-25 - 2022-04-27 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
With a tight focus on late translational to phase II clinical progress, the 2nd Chronic HBV Drug Development Summit returns in person as the definitive industry forum to advance combination therapy and achieve functional cure in hepatitis B virus.
Dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms, this industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts.
From transformative advances in establishing synergistic combination regimens, to navigating clinical endpoints and stopping points, and illuminating the role of immunotherapy to attain durable functional cure, don’t miss your chance to join the conversation.
Harness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences, Vir Biotechnology, VBI Vaccines, Altimmune, Drug Farm, Replicor and many more to guide your strategic decisions and drive clinical progress.
Join us in Boston to forge successful industry collaborations in combination therapy for chronic HBV.
To know more visit: https://ter.li/o1utyk

Novel Format Conjugates Summit
2022-04-25 - 2022-04-27 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
The inaugural Novel Format Conjugates Summit exclusively focuses on the common challenges across early research and development of next generation Non-Traditional ‘ADCs’, or alternative format conjugates approaches for oncology and beyond. This meeting delves into the different technologies of these novel-format conjugates, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities, and the impact an alternative format ADC has on targeting.
As we look to the future of drug development of novel conjugates, you will get the chance to hear the cutting-edge science accelerating the development of Bispecific ADCs, Radio-conjugates, ISACs, SMDCs, Probody conjugates, Liposomal drug conjugates, Oligonucleotide conjugates and many more.
Engage in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days and equip yourself with the tools to develop novel format ADCs with an improved therapeutic potential so we can bring more drugs to patients of unmet needs.
To know more visit: https://ter.li/0811lm

3rd Supply Chain and Logistics for Cell Therapies Summit
2022-04-25 - 2022-04-27 | Crowne Plaza Boston – Woburn, an IHG Hotel, 15 Middlesex Canal Park Rd, Woburn, MA, 01801, United States
Keen to unite with your #celltherapy supply chain community and gain actionable insights for streamlining logistics, implementing digital platforms and optimizing patient operations to establish a reliable global delivery of cell therapies?
Then look no further! The 3rd Supply Chain & Logistics for Cell Therapies Summit is back and taking place in-person for the first time this 25-27 April 2022!
View the full 3-day agenda here: https://ter.li/yp10r2
2022 Agenda Overview:
With exclusive presentations and interactive talks on key industry challenges, gain valuable takeaways from leaders in the field from GlaxoSmithKline, Legend Biotech, Iovance, Gamida Cell, and more. Discuss standardization, review digital system implementation, prepare for upscaling and optimize cryopreservation in person with like-minded supply chain professionals all to maximize efficiency and create a patient-centric end-to-end system.
Download the full event guide to learn more about our speakers, agenda topics, and face-to-face networking opportunities. https://ter.li/yp10r2

2nd Ligase Targeting Drug Development Summit
2022-04-26 - 2022-04-28 | Online, EDT
Whilst the exploiting of this therapeutic modality surges through biopharma and academia, it is essential that we unlock the fundamental challenges within this industry, as this remains a key factor determining success of degraders in the clinic.

The 2nd Ligase Targeting Drug Development Summit returns to Boston in April again uniting industry frontiers and leading minds, as together we discuss, update, and learn how to successfully hijack ligases for therapeutic application, and uncover a critical piece of the puzzle in realizing the full potential of this therapeutic approach.
Filling the gap of an industry-led ubiquitin discussion, we again provide an unrivalled forum to unite leading biopharmaceutical giants, alongside key academics, to share unseen data, collaborative efforts and discuss next steps to successfully select, validate and translate E3’s into a viable therapy.
Join us in Boston to expand your understanding of the ever-broadening ligases field and the fast-improving chemical biology tools to seize the therapeutic value of Ubiquitin E3 ligases and differentiate your pipelines.
To Know more visit: https://ter.li/rm8y7d

Reuters Events: Digital Health 2022
2022-04-26 - 2022-04-27 | Mission Bay Resort, San Diego, California
Join the world’s leading forum for advancing the delivery of digital care
Digital Health’s deployment has been as fast as it has wide. Overnight it has become the central focus for hospitals, clinics and health plans across the nation. The result? Workflows are more complicated than ever. We’re failing on patient engagement. And we still lack a clearly defined digital care payment infrastructure.
Now is the moment to tackle inefficiencies in our use of digital health or risk sub-optimal becoming the new norm. We must not squander the biggest opportunity for the industry’s advancement in half a century.
That’s why we’ve created Reuters Events Digital Health – the place where the standard is set by 300+ executives for the delivery of quality virtual, predictive, affordable and equitable care. Our world-leading forum is where leaders of health systems, payers, policy makers, pharma and health tech converge to realize the transformative potential of technology in healthcare.

5th Neoantigen Summit Europe
2022-04-26 - 2022-04-28 | Leonardo Royal Amsterdam, Paul van Vlissingenstraat 24, Amsterdam, 1096 BK, Netherlands
The 5th Neoantigen Summit Europe, the definitive industry meeting for uncovering the full potential of neoantigens in creating individualised neoantigen vaccines is returning in person!
From understanding the latest clinical insights to reviewing vaccines post-COVID, our 35+ expert speakers and 3-day agenda developed alongside #Vaccibody, #Gritstonebio, #Targovax, #Vaximm, #Immunetune and #OdimmaTherapeutics will help you advance your pipeline to successfully weaponise neoantigens for anti-tumour treatment.
Join 100+ colleagues and take on the next frontier in neoantigen identification and vaccine manufacturing.
Key speakers include: Agnete Fredriksen, Chief Innovation & Strategy Officer, Nykode Therapeutics | Barbara Loesch, Head of Technology and Innovation, Medigene |Jessica Matta, Co-Founder & Chief Executive Officer & Chief Scientific Officer, Odimma therapeutics | Andrew Allen, CEO, Gritstone bio | Peter Sondermann, CEO, Tacalyx GmbH |Sijme Zeilemaker, Chief Executive Officer, Immunetune
Find out more in the event guide here: https://ter.li/gulg78
Visit the official event website here: https://ter.li/s89k61

6th R&D Sourcing & Procurement Summit in Pharma
2022-04-26 - 2022-04-28 | The Bostonian Boston, 26 NORTH STREET, BOSTON, MA, 02109, United States
We are excited for the 6th Advanced R&D Procurement & Sourcing in Pharma Summit returning to Boston in April, reuniting senior leaders to share their stories and lessons learned, and how they implement strategic sourcing to optimize spending and mitigate risks.
As the one and only community dedicated to 100+ R&D procurement, category management, and sourcing professionals, this is your must-attend conference in 2022 to benchmark your SOPs against your peers and stay at the forefront of technology to streamline your procurement processes. Leave this meeting with practical tips to drive scientific innovations with sustainability, optimized spend and strengthened vendor relationships!
Your Unmissable Spotlight Case Studies In 2022:

Establish robust external supplier relationship models to advance your pipeline development with Betrand Rosier, Global Procurement Head, Sanofi
Rebrand procurement to be your scientists’ best business partner with Gerard Cardillo, Vice President, Global Procurement
Explore lessons learned from COVID including strategic investing with Sean Cumbie, Vice President, Global Sourcing & Procurement, NOVAVAX
Develop sourcing & procurement strategies at lightspeed with James Tornos, Vice President, Sourcing & Enterprise Services – Research, Development and Medical Procurement, Pfizer
Deep-dive into driving D&I initiatives, both within companies and through supplier diversity initiatives in an exclusive, interactive workshop led by Manuele Burdese, Senior Director, Head of Business Insights & Analytics Strategic Sourcing & Procurement, Bristol Myers Squibb, Tom Thattacherry, Head, Supplier Diversity, Genentech

To find out how you and your team can get involved download your free event guide or get in touch.

SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference
2022-04-27 - 2022-04-28 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference
Conference: 27 – 28 April 2022
Workshops: 29 April 2022
Boston, MA, USA
http://www.microbiologyeastcoast.com/PJwl
Sponsored by: Bioscience International, Associates of Cape Cod and Microbiologics
Chaired by: Jim Polarine, Senior Technical Service Manager, Head of Microbiology & Sterile Technology, STERIS Corporation
Harnessing existing methods and novel tools in microbial control to assure continuity in product quality and patient safety
SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference is taking place in Boston on April 27-28, 2022, with interactive workshops on April 26, 2022.
Microbiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches.
Ensuring the sterility of the finished product continues to be one of the most critical aspects of drug development, however an array of factors are also sustaining new growth and transformation in this field. The regulatory landscape is changing, firstly with the preparation of Annex 1, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement.
On top of this, the developing integration of automation and robotics into the manufacturing pipeline, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs, are all highlighting the necessity of the field in Pharma.
This industry is ever expanding, join leading experts in 2022 to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with industry professionals, discuss revisions in regulatory and guidance documents, and gain a deeper insight into this corner of the field.
Event Hashtag: #SMiPharmaMicroEC
Key Highlights for 2022:

Review implementation guidance and validation for efficient disinfectant efficacy programs
Uncover principles in best-practice and the benefits of a robust contamination control strategy
Address fungal mould contamination and risk-based tools to tackle spore spreading
Delve into the sterility assurance assessment and holistic closure integrity testing
Explore the impact of the ongoing pandemic and the changing face of the pharma industry
Understand new unique case studies, from contamination control as it relates to microbiome products, to risk-based assessments of traditional microbiological tests
2 Interactive Pre-Conference Workshops on April 26, 2022

Interactive Workshops:
Workshop A: Risk Assessment and Cleaning Validation
Workshop Leader: Fred Ohsiek, SME, Cleaning Validation, North America
Workshop B: USP Microbiology 2022 – Keeping Up with Standards
Workshop Leader: Donald Singer, Chair, General Chapters – Microbiology Expert Committee, US Pharmacopeia and Ecolab Life Sciences
View the full agenda: http://www.microbiologyeastcoast.com
WHO SHOULD ATTEND?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist, Drug Substance External Manufacturer, QC Scientists, Heads of Quality, Business Development Manager, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist

SMi’s 22nd Annual Pain Therapeutics Conference
2022-05-04 - 2022-05-05 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SMi’s 22nd Annual Pain Therapeutics Conference
Conference 4 – 5 May 2022
Workshop: 6 May 2022
London, UK
http://www.pain-therapeutics.co.uk/PJwl
Sponsored by: CHDR
Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc
Novel Compounds and Treatments for Pain: Opioids and the Alternatives
SMi’s 22nd Pain Therapeutics Conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year’s agenda, providing an exciting and comprehensive insight into the pain therapeutics market.
The global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026.
The pain industry was affected by Covid-19, with many individuals suffering with pain conditions, unable to get help or treatment. Therefore, there has been a push to ensure that new and more effective treatments will be made available to patients. There is also still a need to move away from opioid based pain treatment.
Join Europe’s leading Pain Therapeutics Conference in May 2022 to explore new case studies and regulatory perspectives as well as uncover challenges and successes of both pre-clinical and clinical Pain R&D development to equip you with the necessary knowledge to advance R&D in the pain therapeutics industry.
Event hashtag: #SMiPain
Key Reasons to Attend the Conference:

Discover the new treatments available for those with pain diseases, such as migraine, atopic dermatitis and muscle spasms
Develop your knowledge of analgesics for the treatment of pain
Discuss the new alternative treatments for pain and the use of opioids within the field
Network with industry professionals and discuss recent advances in the industry

View the full agenda: http://www.pain-therapeutics.co.uk/PJwl
Who Should Attend?
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

Pain and Migraine
Inflammation
Chronic Pain
Neuropathic Pain
Analgesic pre-clinical development
Anaesthesia and Pain Management
CNS clinical trials
Ion Channel Pharmacology
Pharmacology Intelligence
Translational science
Drug development
Exploratory development

Workshop: Friday 6 May 2022
Molecular and Cellular Pathophysiology of Pain Resolution
Workshop Leaders:
Luda Diatchenko, Canada Research Chair in Human Pain Genetics, Department of Anesthesia, Faculty of Medicine, McGill University
Julio Reinecke, Chief Scientific Officer and Co-Founder, Orthogen
Peter Wehling, CEO and Founder, Orthogen
Ru-Rong Ji, Professor in Anesthesiology, Distinguished Professor of Anesthesiology, Professor in Neurobiology, Professor in Cell Biology, School of Medicine, Duke Neurobiology

SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients
2022-05-09 - 2022-05-10 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients
Conference: 9 – 10 May 2022
London, UK
Website: www.highlypotentapi.com/WLPJ
Chaired by Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
Ensuring Risk-Based, Safety-Driven, High-Quality Operation
SMi is proud to present its 6th Annual Highly Potent Active Pharmaceutical Ingredients, taking place on the 9 – 10 May 2022.
The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety.
SMi Group are delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference will be taking place on 9th – 10th May 2022 in London, UK. The conference will encompass the critical topics including risk assessment, occupational toxicology, engineering controls for containment, facility design, and the impact of pharmaceutical manufacture on the environment.
Benefits of Attending the HPAPI Conference:

Dissect comprehensive hazard assessment and occupational exposure limit determination
Evaluate the increasing trend toward more potent therapies and the consequences of the changing face of pharma
Assess engineering containment controls, from isolators and barriers to fully automated lines
Explore the employment of cleaning validation, organisational controls, and facility as key measure to tackle cross contamination

This two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies.
Early Birds:

Register by 31st January to save £400
Register by 28th February to save £200
Register by 31st March to save £100

Event Hashtag: #SMiHPAPi

LEAP HR: Life Sciences West 2022
2022-05-09 - 2022-05-11 | Marriott La Jolla, 4240 La Jolla Village Dr, La Jolla, CA, 92037, United States
LEAP HR: Life Sciences West is your best opportunity to hear how scaling life sciences organizations are implementing the experimental people strategies required to drive innovation and growth whilst operating in a tight talent market.
Step inside 30+ case studies of the radical, future-focused HR thinking that will empower you to transform your impact and turbocharge scale and innovation in biotech, pharma and medical devices organizations.
Gain access to the HR innovation that is truly making a difference to employees, patients and customers – and leave with a brand-new playbook for the people function to thrive in the fast-paced operating environments of life sciences organizations on the West Coast and surrounding areas.
With a world-class speaker faculty from leading life sciences organizations such as: Atara Biotherapeutics, Gilead Sciences, BridgeBio, Assembly Biosciences, Revolution Medicines, 10X Genomics and many more.
Whether your business is rapidly growing, undergoing serious transition or quickly evolving, LEAP HR: Life Sciences West is your opportunity to plug into a ready-made network of peers who have already solved the talent challenges you’re facing in a candidate-led talent market on the tech-hub West Coast and surrounding areas.
To know more visit: https://bit.ly/3h3w3Nt

Adenosine-Pathway Targeted Cancer Immunotherapy Summit
2022-05-10 - 2022-05-12 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement, enthusiasm, and R&D investment for adenosine-pathway targets.
With reinvigorated confidence in the field, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need.
From analyzing the latest developments in understanding adenosine signaling in the TME, to rationalizing drug combinations that enhance patient responses, and exploring tools that quantify adenosine to select patients, this is the one-stop-shop event for all things adenosine-pathway.
Harness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca, Takeda, Corvus Pharmaceuticals, iTeos Pharmaceuticals, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic.
To know more visit: https://ter.li/q8tgbz

7th Annual 3D Tissue Models Summit 2022
2022-05-10 - 2022-05-12 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Integrate Advanced 3D Models with Scalability & Predictability to Supercharge Your Modeling Toolbox & Enhance Clinical Confidence
Following the FDA’s announcement of ‘Alternative Methods Working Group’ in the summer, 2021, Roche’s newly opened pRED Innovation Center in Basel, and exciting data from Recce Pharma’s anti-infective candidate using organoids, the 7th Annual 3D Tissue Models Summit will return to Boston in May 2022 to reunite the community of drug discovery and development experts. This is the definitive meeting for drug developers to explore and integrate complex 3D models featuring 30+ real-life case studies across 2 dedicated tracks and their lessons learned.
Join us in May to stay ahead of the curve and through 30+ real-life case studies, you will learn and meet trailblazers in 3D models to revolutionize your drug discovery and development protocols, giving you greater confidence in clinical relevancy and accelerating novel treatments to patients in a safe and affordable manner!
To know more visit: https://ter.li/oly672

3rd Manufacturing Engineering & Facility Management in Pharma Summit
2022-05-10 - 2022-05-12 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Following innovative technological breakthroughs and the FDA’s Emerging Technology Program, the pharmaceutical industry is experiencing a renaissance period with an unprecedented level of investments in new builds and next-generation technology to support novel pipeline progression.
The ability to commission a modern, flexible, compliant facility on time and a budget have never been so critical to drug developers and patients worldwide.
The 3rd Manufacturing Engineering & Facility Management in Pharma Summit is the industry’s first definitive discussion and networking forum designed to reunite leaders in the manufacturing and facilities fields in person after two years to share scientific breakthroughs and address challenges the industry is facing. With the pharmaceutical industry entering Pharma 4.0, technology advances and facilities designs must adapt to a digital, remote world to enhance tomorrow’s CGT pipeline.
Designed alongside the likes of Bayer, AstraZeneca, and Catalent, this industry-focused forum allows you to discuss novel cutting-edge technologies, the latest approaches of engineering modular, flexible facilities and address the supply chain crisis.
With 22+ hours of content, 3 interactive workshops, and over 2 hours of networking with key industry leaders, this comprehensive forum will uniquely combine leaders in the manufacturing, engineering, and facilities fields in one setting to share lessons learned, case studies, and advancements in the field.
Join 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from 20+ expert speakers on sharing technology innovations that are transforming the manufacturing field, maximizing productivity and capital efficiency through excellent engineering and facility management, and collaborating with stakeholders to ensure on-time, on-budget commissioning, and validation.
Join us this May to maximize your facility flexibility, asset lifespan, productivity & compliance through excellent engineering, robust validation & technology adoption!
To know more visit: https://ter.li/qe5ezy

Injectable Drug Delivery Conference 2022
2022-05-11 - 2022-05-12 | London, United Kingdom
SMi Group Introduces the 4th Annual…
Injectable Drug Delivery Conference 2022
11th May to 12th May 2022,
London, United Kingdom
www.injectable-drug-delivery.com/
Innovations in Formulation and Device Design for Enhanced Subcutaneous Delivery
As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds.
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027.
This year’s event will highlight the significance of sustainability within the injectable drug delivery industry, whilst also providing regulatory insight on the changes that have occurred. There will be an additional focus on the impact that covid has had on the success within this industry over the past year. The conference will also highlight successes within the industry and the formulation challenges of long-lasting, highly viscous and high-volume drug delivery.
The benefits of attending:

Discover the new technologies and latest injectable devices being used within the industry
Develop your understanding of high-volume and long-acting injectable compounds
Explore the sustainable possibilities that can be adapted within the industry for a green future
Delve into the world of biologics and biosimilars and what these mean for the injectable drug market
Network with key industry leaders and discover the leading companies within the injectables space

Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:

Autoinjectors
Wearables
Device Engineering
Human Factors
CMC
Injectables
Sterile Manufacturing
Packaging
Regulatory Affairs

Featured Speakers:

Alexander Zuern, Device testing manager, Novartis International AG
Andrew Warrington, Project Leader & Patient Advocate, Novartis
Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Bjorg K Hunter, Regulatory Manager, Devices, GSK
Blake Green, Senior Manager Regulatory Affairs, Amgen
Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
Christopher Muenzer, Senior Device Technology Manager, Novartis
Joel Richard, Head of Technical & Pharmaceutical Operations, MedinCell
Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
Rebecca Moses, Director, Core Human Factors Inc.
Rupal Nguyen, Principal Engineer, Allergan
Stefania Ragone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
Tina Arien, Principal Scientist, Janssen Pharmaceutica
Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

Past attendees have included
Advanz Pharma; Amgen; AstraZeneca; BD – Becton Dickinson; Bd Medical-Pharmaceutical Systems; BD Technologies and Innovation; Becton Dickinson; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chugai Pharmaceutical CO. LTD.; Congenius; Core Human Factors; F Hoffmann -La Roche Inc; GlaxoSmithKline; Glenmark Pharmaceuticals Inc.; GSK; Haselmeierá; Haughton Design Ltd; Ipsen Biopharm Limited; Janssen Pharmaceutica; Janssen Pharmaceutica NV; Legacy Allergan/AbbVie; LEO Pharma A/S; MedinCell; Merck; Merck Connected Health & Devices; MHRA; Micropore Technologies Ltd; Novartis / DD&C; Novartis International AG; Novo Nordisk Pharma; Owen Mumford; Pfizer UK Limited; Raumedic AG; Roche; SABIC; Sabic SHPP; Sandoz – A Novartis Company; Sanofi; Sanofi SWI; Team Consulting; Teva Pharamceuticals; UCB; Vetter Pharma-Fertigung GmbH & Co. KG; Zealand Pharma A/S
Additional Contact Info:
T: +44 (0)20 7827 6088
E: rjones@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMiInjectables

4th Microbiome Movement - Maternal & Infant Health Summit 2022
2022-05-17 - 2022-05-19 | DoubleTree by Hilton Hotel Boston – Bedford Glen, 44 Middlesex Turnpike, Bedford, MA, 01730, United States
The 4th Microbiome Movement - Maternal & Infant Health Summit is returning, in person, on May 17-19, 2022 with the goal of uniting expert industry and academic minds to tackle the biggest challenges in the understanding, targeting and treatment creation for the maternal and infant microbiome.
This summit is the only place where you will find such a collaborative and engaged group of speakers and attendees with a diverse group of backgrounds in academia, drug discovery, nutritional product creation and clinical health care – you can be sure to hear a wide range of opinions and perspectives.
Ensure you do not miss out on the latest and greatest work in fields relating to the microbiome such as maternal health, the vaginal microbiome, harnessing the microbiome for preventative treatment, breastmilk, pre-term birth and infant allergic/metabolic disease.
To know more visit: https://ter.li/81ntsl

Pharma Clinical 2022
2022-05-17 - 2022-05-19 | Virtual
The pandemic response has accelerated technology adoption in clinical trials, but we have neglected patient needs by failing to develop co-created, data-driven, standardised and accountable trial designs.
In the face of rethinking clinical strategy, our mission is clear: it’s time to develop a better system. We must establish new industry-wide benchmarks now, leverage recent digital innovations, and ensure permanent cultural change toward patient- centric trials. If we do not act immediately, we risk losing this opportunity to rebuild patient trust.
This is why we are bringing together the world’s clinical leadership at Reuters Events: Pharma Clinical 2022 (May 17-19, Virtual). We aim to define the new standards in digital and patient innovation for clinical transformation. Join 500 + clinical innovators and 40 + expert speakers to create an accountable clinical ecosystem where patient diversity, centricity and empowerment aren’t just slogans – they are core principles.
To know more visit: https://bit.ly/3npeUkP

4th Treg Directed Therapies Summit
2022-05-17 - 2022-05-19 | Embassy Suites by Hilton, Boston Logan Airport 207 Porter St, Boston, MA, 02128, United States
As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy.
The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally.
With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:

Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy

200+ senior level drug developers will be uniting in May to chase the holy grail of Treg-directed therapies. Don’t miss your chance to network with the avant-garde to inform your Treg pipeline and capitalize on the shared knowledge of this collaborative community.
To know more visit: https://ter.li/fhrzm3

Medical Device Software Development Summit 2022
2022-05-17 - 2022-05-19 | DoubleTree by Hilton Hotel Boston, North Shore, 50 Ferncroft Rd, Danvers, MA, 01923, United States
Bringing together a senior audience of cutting-edge device manufacturers, and featuring a unique program focused on real-life use cases, the 2022 Medical Device Software Development Summit offers you a toolkit for designing compliant, innovative, and secure medical device software, enabling you to move one step ahead of emerging trends.
So whether you’re a part of a regulatory, quality, or technical team, join the Medical Device Software Development Summit to meet like-minded peers who are pioneering new technologies and methodologies to develop innovative medical device software, ultimately bringing value to patients.
5 key topics at Medical Device Software Development Summit

Navigate Regulations when Behind Innovation
Continue to push the boundaries of innovation with AI-enabled medical devices
Understand and implement agile software development methodologies
Implement risk analysis into the software development lifecycle
Focus your attention on device security to avoid breaches

To find out how you and your team can get involved download your free event guide or get in touch.

Customer Engagement Europe 2022
2022-05-24 - 2022-05-25 | Hilton Tower Bridge, London 5 More London Riverside, Tooley St, London, SE1 2BY, United Kingdom
Deliver enduring behavioral change with agile, personalized engagement
Precise, Personalized and Proactive- the future of customer engagement is a digitally enabled, hybrid omnichannel strategy.
Heard that all before?
From measuring clicks to measuring behaviour change, the way we think about customer preference has forever been changed. Across marketing, commercial, and medical, the skills we need to deliver on changing HCP expectations are aligning. Now is the time to do the same for our strategy.
Reuters Events Pharma: Customer Engagement Europe 2022 (London, May 24-25) is the only pharma event bringing together functions to drive the future of agile engagement. Join us to deliver a hybrid, insight driven, modularized model that incorporates iterative insights, delves deeper into data, empowers our field forces with digital empathy, prioritizes innovation, and equips our teams for industry leadership.
To know more visit: https://events.reutersevents.com/pharma/customer-engagement-europe

Customer Engagement Europe 2022
2022-05-24 - 2022-05-25 | Hilton Tower Bridge, London 5 More London Riverside, Tooley St, London, SE1 2BY, United Kingdom
Precise, Personalized and Proactive- the future of customer engagement is a digitally enabled, hybrid omnichannel strategy.
Heard that all before?

From measuring clicks to measuring behaviour change, the way we think about customer preference has forever been changed. Across marketing, commercial, and medical, the skills we need to deliver on changing HCP expectations are aligning. Now is the time to do the same for our strategy.
Reuters Events Pharma: Customer Engagement Europe 2022 (London, May 24-25) is the only pharma event bringing together functions to drive the future of agile engagement. Join us to deliver a hybrid, insight driven, modularized model that incorporates iterative insights, delves deeper into data, empowers our field forces with digital empathy, prioritizes innovation, and equips our teams for industry leadership.
To know more visit: https://bit.ly/3qz6d9B

Next Generation RNA Therapeutics Summit
2022-05-24 - 2022-05-26 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
With novel RNA-based modalities having seen extraordinary development in the last 18 months, there has never been a more important time for the RNA community to unite, share learnings and accelerate the field towards successful proof of concept and effective therapeutic development.
Stay ahead of the curve with novel RNA therapeutics and vaccines that offer exceptional stability and durability whilst addressing key delivery, pharmacology and scalability challenges to successfully translate safe and effective next generation RNA therapeutics into the clinic.
The Next Generation RNA Therapeutics Summit is the only meeting to deep dive into the specific challenges and opportunities associated with novel RNA modalities, welcoming cutting-edge biotech giants such as Pfizer, BioNTech, Moderna Therapeutics and Replicate Bioscience to share unmissable insights on circular RNA, tRNA and self-amplifying RNA therapeutics and vaccines.
Join 80+ thought leaders under one roof as they set the scene for next generation RNA therapeutics. This unique group of Directors, Heads and VPs of RNA Therapeutics, Chemistry, Delivery and New Therapeutics will unite at this must-attend event for the RNA community. Don’t miss out!
To find out more, visit: https://ter.li/0ei6ql

4th Annual Cell Engager Summit
2022-05-24 - 2022-05-26 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
4th Annual Cell Engager Summit May 24-26, 2022 | Boston, MA

The 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies, including CD19, CD20, BCMA, CD33, and CD123.

This must-attend meeting will provide a comprehensive understanding of the development of multi-specific cell engaging therapeutics in liquid and solid tumor indications, with the goal of bringing early-stage innovation to the clinic.
Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries.
You will leave this meeting with key steps to improving safety and efficacy in the solid tumor microenvironment through lower CRS, greater dose, and lower TMDD by targeting tumor antigens such as HER2 and EGFR, and modifying co-stimulatory receptors (for example CD137/4-1BB, CD28).
Ensure your Cell Engager program reaches full clinical potential through learning from the pioneers of immunotherapy.
To know more visit: https://ter.li/d3i1x0

Hippo Pathway Targeted Drug Development Summit
2022-05-24 - 2022-05-26 | DoubleTree Suites by Hilton Hotel Boston, 400 Soldiers Field Road, Cambridge, Boston, MA, 02134, United States
It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Although once seen as an elusive pathway, emerging novel data and research is forging a wider and more developed mechanistic understanding of it. New avenues have been opened to evolve the landscape of targetable nodes and therapeutic interventions, from small molecule approaches to novel modalities targeting the TEAD transcription complex.
With the clear therapeutic potential of this highly attractive and targetable pathway, investment, collaboration, and interest has flooded in through biopharma and academia – and what was once an unexploited space is now seeing an abundance of promising therapeutic interventions.
The inaugural Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry dedicated forum focused on accelerating the mechanistic understanding and potential of the Hippo signaling pathway to enhance the discovery, translation, and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.
Uniting the leading minds of large pharma, biotech and academia, this unrivalled conference will showcase the pioneering discoveries, critical novel findings and promising clinical candidates drugging YAP, TAZ & TEAD transcription factors and other high-value targets within the Hippo pathway. With Keynote sessions from Ikena Oncology, Spring Works Therapeutics, Cedilla and Vivace Therapeutics, this is a unique opportunity to hear first-hand the development of novel YAP/TAZ-TEAD antagonists, from discovery to the clinic.
Over 80 key stakeholders from BridgeBio, Cancer Research UK, AstraZeneca, Orion Pharma, Faze Medicines, Inventiva, Zentalis Pharmaceuticals, Basilea Pharmaceuticals and many more have already confirmed their places as the industry continues to unlock critical pieces of the puzzle in the understanding and exploitation of this signaling pathway.
Together, we will unite to learn, debate, and discuss; leverage the therapeutic opportunity of this pathway; and critically address the huge unmet clinical need.
To know more visit: https://ter.li/4tdp3b
